Introduction
Aluminum phosphide (AlP) is used widely throughout the world as a pesticide and fumigant because of its efficacy and low cost (1) . AlP is one of the most frequently reported causes of acute chemical poisoning in Asia (2) (3) (4) . In Iran, it is available in 3-g tablets containing 1 g of AlP and known as "rice tablet"; it causes acute poisoning with a high mortality rate (5) (6) (7) .
AlP toxicity is due to liberating phosphine (PH 3 ) gas after its reaction with moisture, water, or hydrochloric acid in the stomach (8, 9) . The major of mortality occurs during the first 12-24 h after exposure and is mostly due to cardiovascular and respiratory involvement (8, 9) .
The exact mechanism of phosphine toxicity is not clear and some mechanisms are reported (8, 9) . Previous studies suggested that the induction of oxidative stress has the main role in AlP toxicity (10, 11) , which is emphasized by recent studies (12) (13) (14) (15) .
As there is no specific antidote for acute AlP poisoning, its treatment is mainly supportive and symptomatic (1, 8, 9) . By considering the induction of oxidative stress as the main mechanism of AlP toxicity and with regard to the role of vitamin E in the enzymatic antioxidants defense and function as a free radical scavenger (16) (17) (18) , its use may have a therapeutic effect in the treatment of AlPpoisoned patients.
The aim of the present study was to investigate the therapeutic effects of vitamin E in acute human AlP poisoning.
Materials and methods

Patients
This was a prospective, randomized, control open label trial on acute AlP intoxicated patients that were treated in the intensive care unit (ICU) over a 1-year period.
Acute AlP-intoxicated patients above the age of 12 years who were admitted during the first 6 h after exposure with no advanced medical management for AlP poisoning in any medical center before admission were included in this study. The exclusion criteria were history of diabetes mellitus, cardiovascular, respiratory, renal, and hepatic failure, substance abuse, and co-ingestion.
The diagnosis was confirmed based on history of exposure, clinical manifestations, laboratory findings, and other circumstantial evidence such as availability of a poison bottle or a label. In fatal cases, toxicological analysis and a histopathological examination were performed. A positive silver nitrate test for PH 3 gas on stomach contents and tissues along with the liver postmortem histopathological findings confirmed the AlP poisoning.
According to the mentioned criteria, 36 patients were included in the study consecutively. Each patient with an even file number was included in the vitamin E treatment group (n = 20) and the patients with odd file numbers were included in the control group (n = 16).
Study design and treatments
All the patients received gastric decontamination with sodium bicarbonate (44 mEq), permanganate potassium (1:10,000), and activated charcoal (1 g/kg) in the first 6 h after exposure. All the patients were admitted to the ICU, as they needed intubation, mechanical ventilation, and intensive monitoring. They were treated with the same protocol (magnesium sulfate 4-6 g by IV infusion daily, calcium gluconate 4 g by IV infusion daily, adequate hydration, and norepinephrine 10 µg/min as vasopressor) under the supervision of the same physicians and nurses. The described treatments were based on the clinical toxicology department protocols. In the vitamin E treatment group, vitamin E (as DL-alpha tocopheryl acetate, 100 IU/mL, OSVAH Pharmaceutical Co. Tehran, Iran; 400 mg/IM, every 12 h) was administered up to 72 h. We followed the patients up to discharge from the hospital or death.
The protocol of the study was approved by the ethical committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sampling and bioanalysis
Blood sampling was performed at the admission on hospital and repeated each 24 h up to 72 h of hospitalization in the ICU. Venous blood samples (5 mL) were collected in different heparinized tubes and then plasma samples were separated via centrifugation at 3500 rpm for 10 min and frozen at -80 °C. On average, the time interval between sampling and analysis was 1 week. Lipid peroxidation in the plasma in two groups was evaluated by the thiobarbituric acid reactive substances (TBARS) method (19) . First 250 µL of 20% trichloroacetic acid (TCA) in 10 mL of sodium sulfate (2 M) was added to 0.5 mL of plasma. After precipitation of the protein with TCA, washing with 300 µL of sulfuric acid (0.05 M) was performed. Then 300 µL of thiobarbituric acid (TBA) (0.67% w/v) solution was added to the mixture. The mixture was incubated in a boiling water bath for 30 min. After cooling, the samples were extracted with n-butanol and centrifuged at 3500 rpm. The absorbance was read at 530 nm by ELISA microplate reader (Synergy, BioTech Instruments Inc, Germany). 1,1,3,3-Tetramethoxy propane was used for drawing the calibration curve. Malondialdehyde (MDA) was expressed as micromoles of MDA per liter of plasma.
The total antioxidant capacity (TAC) of plasma was evaluated using the ferric reducing ability of plasma (FRAP) assay (20) . Ferric tripyridyltirazine (Fe 3+ -TPTZ) complex is reduced to the blue color marker ferrous (Fe   2+   ) form at acidic pH. To 50 µL of plasma was added 1500 µL of freshly prepared FRAP reagent [25 mL of acetate buffer (pH = 3.6, 300 mmol/L), 2.5 mL of FeCl 3 , 6H 2 O (20 mmol/L), 2.5 mL of TPTZ (10 mmol/L TPTZ in 40 mmol/L HCl)]. After 15 min incubation at 37 °C in a water bath, absorbance was determined by ELISA microplate reader (Synergy, BioTech Instruments Inc, Germany) at 593 nm. Then samples were placed at 37 °C in the water bath and absorption was measured after 4 min. FRAP values were measured by calculation of the absorbance change in plasma sample compared with that of trolox standard (20) .
Data collection and statistical analysis
We collected patients' information regarding sex, age, cause of poisoning, number of ingested AlP tablets, time interval between exposure and beginning of treatment, route of exposure, clinical and laboratory findings at admission and during the first 24 h of hospitalization, duration of hospitalization, and outcome and prepared qualifying case records. All data were kept confidential during the study.
The Glasgow Coma Scale (GCS) and Simplified Acute Physiology Score II (SAPS II ) were calculated at admission (21, 22) . All data were analyzed with SPSS version 12. Data were expressed as mean ± SD for quantitative variables and as frequency and percentage for qualitative variables. The chi-square test was used for statistical comparison of qualitative variables. The normal distribution of quantitative variables was tested by KolmogorovSmirnov test. The Mann-Whitney U-test was used for nonparametric variables and the independent Student's t-test was used for parametric variables. P values of 0.05 or less were considered statistically significant.
Results
In the present study, 36 patients (13 men, 23 women) with acute AlP poisoning were included, of whom 20 (5 men, 15 women) were in the treatment group and 16 (8 men, 8 women) were controls. The route of exposure was deliberate ingestion in all patients. The main clinical manifestation was vomiting, observed in the most of the patients in the treatment and control groups (90% vs. 87.5%, respectively). Table 1 summarizes the demographic, clinical, and $ Time between onset of poisoning and admission to hospital, SD = Standard deviation * The difference between the two groups is significant at P < 0.05 ** The difference between the two groups is significant at P < 0.005 ▲ Chi-square test was used for statistical analysis ♦ Mann-Whitney U-test was used for statistical analysis • t-test was used for statistical analysis laboratory results. SAPS II was determined in the treatment (4.7 ± 2) and control groups (5.05 ± 3.13). The results showed no significant difference (P = 0.68). Systolic blood pressure (SBP) significantly increased during the first 24 h in the treatment group (89.16 ± 17.95 mmHg at admission vs. 98.95 ± 15.45 mmHg 24 h after onset of poisoning, P < 0.05). The results also showed that there was no significant difference between the two groups due to SBP 24 h after the onset of poisoning (98.95 ± 15.45 mmHg in the treatment group vs. 89.21 ± 20.25 mmHg in the control group, P = 0.13).
We observed significant increases in diastolic blood pressure (DBP) in the treatment group (55.76 ± 11.03 mmHg at admission vs. 60.63 ± 13.58 mmHg 24 h after the onset of poisoning, P < 0.05) and significant decreases in DBP in the control group (60.67 ± 10.91 mmHg at admission vs. 50.43 ± 12 mmHg 24 h after the onset of poisoning, P < 0.05). The data showed a significant difference between the two groups with regard to DBP 24 h after the onset of poisoning (P < 0.05).
The results showed a significant difference in blood pH between the treatment and control groups (7.43 ± 0.04 vs. 7.33 ± 0.1, P < 0.001) 24 h after onset of poisoning. In addition, there was no significant difference between the two groups due to PCO 2 (36.24 ± 7.57 mmHg in the treatment group vs. 34.19 ± 6.91 mmHg in the control group, P = 0.4). We observed a significant difference in serum bicarbonate between the two groups 24 h after the onset of poisoning (24.22 ± 6.55 mEq/L in the treatment group vs. 18.91 ± 5.62 mEq/L in the control group, P < 0.05).
There was no significant difference in the TAC of plasma in the treatment and control groups at admission (Table 2) . Twenty-four hours after the onset of poisoning, the TAC of plasma in the control group was significantly higher than that in the treatment group (Table 2) .
At admission, the plasma MDA level was not significantly different between the treatment and control groups. The plasma MDA level significantly decreased in the treatment group and it significantly increased in the control group. The plasma MDA level in the treatment group was significantly lower than that in the control group 24 h after the onset of poisoning ( Table 2) .
The percentage of patients who required intubation and mechanical ventilation was significantly lower in the treatment group than in the control group (30% vs. 62%, P < 0.05). In addition, the duration of intubation and mechanical ventilation in the treatment group was significantly lower compared to the control group. The total dose of norepinephrine was not significantly different between the two groups (Table 3) .
Although the duration of hospitalization was not significantly different between the two groups (Table 3) , the results showed that most of the fatality occurred during the first 12 h after admission in the control group, and in the treatment group most of the fatality was observed 20 h after admission (Figure) . In addition, the data showed that the mortality rate was significantly lower in the treatment group than in the control group (15% vs. 50%, P = 0.02).
Discussion
AlP poisoning is a major health problem with a high mortality rate in Iran and other countries (2) (3) (4) 6) . Unfortunately, to date, there is not a specific antidote for treatment of this type of fatal poisoning and the only therapeutic measures are supportive and symptomatic (9) . In this regard, performing studies that evaluate other therapeutic protocols is necessary.
There are many suggested mechanisms for AlP poisoning. One of the most important mechanisms is involvement of oxidative stress (10) (11) (12) (13) (14) . From this viewpoint, the antioxidants may have a therapeutic role in the treatment of AlP poisoning (10, 12) . * The difference between two groups is significant at P < 0.05 ■ There is no significant difference between the treatment and control groups at admission ▲ There is a significant difference between the treatment and control groups 24 h after the onset of poisoning at P < 0.05 Mann-Whitney U-test was used for all the statistical analysis Previous studies showed that vitamin E had a protective role in the in vivo or in vitro toxicity of some poisons through its antioxidant activity and lowering cell death by decreased the levels of MDA, reactive oxygen species production, and lipid peroxidation (18, (23) (24) (25) .
In the present study, we aimed to evaluate the efficacy of intramuscular administration of vitamin E as an antioxidant agent in patients with acute AlP poisoning.
The results showed significant rises in SBP and DBP in the treatment group 24 h after the onset of poisoning, which could be due to the role of vitamin E in reduction of myocardial and vessels injury through the decrease in lipid peroxidation (26, 27) .
The results in the control group showed progressive metabolic acidosis during the first 24 h after the onset of poisoning, which could be due to tissue hypoperfusion.
In the present study, the TAC and MDA levels at admission showed no significant difference between the two groups. In addition, the results showed that the serum levels of MDA were significantly decreased after 24 h in the treatment group, while in the control group they were significantly increased. These results are in concordance of our previous study, in which the administration of N-acetyl cysteine as an antioxidant resulted in similar findings (12) .
Vitamin E administration decreased the necessity for intubation and mechanical ventilation and was associated with a decrease in duration of intubation and mechanical ventilation. This result was similar to that of our previous study (12) . Although in the previous studies mortality rates of 60%-80% were reported in the AlP poisoning cases with conventional supportive and symptomatic treatment (7, 28, 29) , in the present study administration of vitamin E significantly reduced the mortality rate in the treatment group compared to the control group (15% vs. 50%, respectively).
In conclusion, the present study showed that the administration of vitamin E along with supportive treatment decreased the mortality rate and so it could be considered in the treatment of acute AlP poisoning in combination with other therapeutic protocols.
The limitations of this study were small sample size and lack of blinding in the study design.
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